Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up | Breast Cancer Research and Treatment
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Progression-free survival (PFS) in the PALOMA-1 phase II trial... | Download Scientific Diagram
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib | npj Precision Oncology
Progression-free survival in the PALOMA-1 study (palbociclib +... | Download Scientific Diagram
full prescribing information for IBRANCE
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | Breast Cancer Research
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO
Lead team presentation
MA17R: Disease-Free Survival with Extended Adjuvant Letrozole in Postmenopausal Women with Early-Stage Breast Cancer (BC) Letrozole (n = 959) Placebo (n. - ppt download
Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study - Takahashi - 2020 - Cancer Medicine - Wiley Online Library
Figure 2 from PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients | International Journal of Clinical Oncology
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates | Breast Cancer Research | Full Text
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
PALOMA-3: PFS by Subtype Distribution. a Intrinsic subtype distribution... | Download Scientific Diagram
Yara Abdou, MD on X: "PALOMA-2: OS update ❗️Palbo+ET did NOT significantly improve OS compared to PBO+ET ❓Is there a difference btw CDK4/6i ⚠️Interpret with caution given missing survival data and distinct
